The Global Immuno-oncology Therapeutics Market--Checkpoint Inhibitors
LONDON, Sept. 29, 2016 /PRNewswire/ -- The Next Generation of Cancer TherapiesImmuno-oncology is based on the premise that tumors escape detection by the immune system, contributing to their growth and progression. Checkpoint inhibitor pathways act as the checks and balances that allow T-cells to recognize foreign substances or tumors. This global study looks at the immune-oncology therapeutics pipeline for checkpoint inhibitors in the drug classes CTLA-4, PD-1/PD-L1, LAG-3, and TIM-3, identifying companies and products in development, dollars spent at each phase (preclinical through launch), cost and reimbursement implications to payers, challenges to commercialization, and opportunities for pharmaceutical, biotech, or diagnostic companies as oncology treatment algorithms evolve. The study period is 2011 to 2020.
Immuno-oncology is based on the premise that tumors escape detection by the immune system, contributing to tumor growth and progression.
Checkpoint Inhibitor Market: Market Snapshot, Global, 2015 Checkpoint pathways constitute the "checks and balances" segment of the immune system which facilitates the recognition of foreign substances or tumor cells by the T-cells.
Approximately 245 companies globally are developing therapies in the checkpoint inhibitor area, with over xx% in the United States. GLOBOCAN reported in 20xxan estimated 14.1 million new cases of cancer per year, with the projected incidence to rise to xx million by the year 20xx
The overall checkpoint inhibitor market is over $xx billion and is set to grow at a CAGR of xx% (20xx–20xx.
- Although the US dominates the market, because of the exorbitant drug development investments, new opportunities do exist in Europe and Japan where cancer incidence is increasing.
- Analysts have estimated the potential of the total immuno-oncology market peak sales to be worth $xx to $xx billion by 20xx with more product approvals and indication expansions for existing products.
Download the full report: https://www.reportbuyer.com/product/4000248/About ReportbuyerReportbuyer is a leading industry intelligence solution that provides all market research reports from top publishershttp://www.reportbuyer.com For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: email@example.com Tel: +44 208 816 85 48 Website: www.reportbuyer.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/the-global-immuno-oncology-therapeutics-marketcheckpoint-inhibitors-300336901.html